Last reviewed · How we verify
ProDiax-23 (PPSV23)
PPSV23 is a pneumococcal polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae.
PPSV23 is a pneumococcal polysaccharide vaccine that stimulates the immune system to produce antibodies against 23 serotypes of Streptococcus pneumoniae. Used for Prevention of invasive pneumococcal disease in adults and children ≥2 years, Prevention of pneumococcal pneumonia and bacteremia.
At a glance
| Generic name | ProDiax-23 (PPSV23) |
|---|---|
| Sponsor | Korea University Guro Hospital |
| Drug class | Polysaccharide vaccine |
| Target | Streptococcus pneumoniae capsular polysaccharides (23 serotypes) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains purified capsular polysaccharides from 23 different serotypes of pneumococcus conjugated to a carrier protein or presented as a polysaccharide mixture. Upon administration, it activates both B and T cell responses to generate protective antibodies and cellular immunity against the most common disease-causing pneumococcal strains, reducing the risk of invasive pneumococcal disease.
Approved indications
- Prevention of invasive pneumococcal disease in adults and children ≥2 years
- Prevention of pneumococcal pneumonia and bacteremia
Common side effects
- Injection site pain, erythema, or swelling
- Fever
- Myalgia or arthralgia
- Headache
- Fatigue
Key clinical trials
- Immunogenicity After Revaccination With 23-valent Pneumococcal Polysaccharide Vaccine: Healthy Elderly People Versus Diabetic Patients (PHASE4)
- Post-marketing Safety Evaluation of Pneumococcal Vaccines Among Children and Elderly Adults.
- Study Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ProDiax-23 (PPSV23) CI brief — competitive landscape report
- ProDiax-23 (PPSV23) updates RSS · CI watch RSS
- Korea University Guro Hospital portfolio CI